Oncology
ASCO 2026: All about DNA damage response, with Luke Piggot
Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Patients
ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee
A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.
Oncology
ASCO 2026: Three ADC approvals in five days, with Ken Keller...
At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.
Oncology
ASCO 2026: Can a blood test spot cancer early? with Dr Peter...
Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.
Oncology
ASCO 2026: A potential functional cure in endometrial cancer...
For GSK, ASCO 2026 was about long-term follow-up data, with new data from ongoing trials of Jemperli and Blenrep.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
